✦ LIBER ✦

Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: results from a randomized, controlled phase II study in patients with breast cancer and bone metastases

✍ Scribed by Cynthia Campbell-Baird; Allan Lipton; Makan Sarkeshik; Haijun Ma; Susie Jun

Book ID: 118628280
Publisher: Frontline Medical Communications, Inc.
Year: 2010
Tongue: English
Weight: 131 KB
Volume: 7
Category: Article
ISSN: 1548-5315
DOI: 10.1016/s1548-5315(11)70560-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized Phase II Trial of Denosumab i

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

✍ Fizazi, K.; Lipton, A.; Mariette, X.; Body, J.-J.; Rahim, Y.; Gralow, J. R.; Gao 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 235 KB

P105 Incidence of acute-phase reactions

P105 Incidence of acute-phase reactions following treatment with denosumab or zoledronic acid: results from a randomized, controlled phase 3 study in patients with advanced cancer or multiple myeloma

✍ H. Polderdijk; C. Kofler; J. Wang; M. Sarkeshik; H. Yeh 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 59 KB

AOSOP6 Results from the 2-year open-labe

AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab

✍ A.T. Stopeck; A. Lipton; M. Martín; J-J. Body; A. Paterson; G.G. Steger; K. Tonk 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB